查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1837164

尿道感染市場：按治療、年齡層、性別和最終用戶分類－2025-2032 年全球預測

Urinary Tract Infection Market by Treatment, Age Group, Gender, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，尿道感染市場將成長至 216.6 億美元，複合年成長率為 7.14%。

主要市場統計數據
基準年2024年 124.7億美元
預計2025年 133.4億美元
預測年份：2032年 216.6億美元
複合年成長率（%） 7.14%

簡要概述尿道感染的臨床動態變化、患者期望以及影響診斷和治療途徑的相關人員的優先事項

尿道感染(UTI) 是貫穿初級保健、門診和急診的臨床挑戰。臨床情勢由以下因素決定：不斷發展的診斷方法（優先考慮快速症狀分類和就地檢驗）、不斷擴展的治療套件（兼顧療效和抗菌藥物管理）以及患者對可及性和耐受性治療方案的期望不斷提高。這些匯聚的力量正在塑造臨床醫生、支付方和衛生系統在評估治療途徑和服務模式時如何設定優先事項。

臨床醫生擴大使用將症狀評估與針對性檢測相結合的整合工作流程，以區分併發症病例和需要升級治療的病例。同時，藥物和非藥物治療方案也越來越受到關注，不僅因為它們可以緩解症狀，還因為它們在減少復發和支持抗菌藥物管理方面發揮著重要作用。患者和看護者正在尋求能夠快速控制症狀、副作用最小且易於給藥的治療方法，這些偏好正在影響處方行為和產品開發。

在營運方面，醫療保健提供者正在調整護理路徑，以在適當的情況下適應遠端醫療、遠端監控和居家管理，這凸顯了製定完善的臨床指南和患者教育的重要性。這些動態共同為從研發到分銷再到臨床實施的整個價值鏈的策略決策奠定了基礎。

新興的臨床、技術和行為變化從根本上改變了尿道感染治療格局和相關人員的決策。

尿道感染)領域正在經歷一場變革，這得益於診斷技術的進步、對抗生素管理的重新重視以及數位化醫療推動的患者行為的改變。快速分子診斷和照護現場正在減少診斷的不確定性，使臨床醫生能夠更精準地制定治療方案，並避免不必要的廣譜抗生素使用。這種轉變強化了臨床對標靶藥物的偏好，並支持在適當的情況下將非抗生素輔助藥物納入治療方案。

行為轉變同樣重要。患者如今期望更快獲得治療，更透明地了解風險和效益，並做出符合其生活方式偏好的選擇。遠端醫療已發展成為一種可行的初步評估和追蹤手段，鼓勵將遠端系統管理與必要時的現場升級相結合的護理模式。同時，供應鏈創新，包括製造商和經銷商之間更緊密的合作，正在幫助緩解暫時的供不應求，並確保護理的連續性。

技術整合正在重塑臨床工作流程。電子健康記錄和決策支援系統正在更新，以反映管理原則並促進適當的診斷檢測。這些工具有助於更好地監測依從性，並支持真實世界證據的收集，從而為指南的迭代更新提供資訊。這些變革力量的匯聚正在創建一個生態系統，在這個生態系統中，臨床有效性、病患體驗和營運韌性相互依存。

2025 年美國關稅對醫藥供應鏈、籌資策略和醫療機構臨床可累積影響

2025年美國加徵關稅將使尿道結石治療供應鏈、籌資策略和製造地決策更加複雜。影響原料、活性藥物成分和成品進口的關稅可能會改變採購的經濟性，促使製造商和經銷商重新評估籌資策略，並評估轉移生產或尋找其他合格供應商的可行性。因此，醫療系統和支付方可能需要調整其合約方式，以維持醫療服務的可及性和連續性。

除了採購之外，關稅還可能影響庫存計劃週期和商業合約結構。企業可以提高安全庫存水準或多元化供應商組合，以降低貿易政策波動帶來的風險，因為貿易政策波動會影響營運成本和物流能力。製造商和服務提供者可能會重新考慮近岸外包或在地化策略，以降低關稅風險，但此類措施需要前置作業時間、資本投入和監管調整，而這些措施可能會限制回應能力。

臨床醫生和處方人員應預見產品供應或替代品的潛在變化，這可能需要調整方案並加強患者溝通。付款人和醫療系統可以加強與製造商的合作，設計應急計劃，以確保第一線藥物的可及性，同時與管理目標保持一致。最終，由價格主導的變化強化了供應鏈敏捷性、多元化採購和積極主動的相關人員參與的價值，從而在政策驅動的市場波動期間保障病患醫療。

深入細分洞察治療方式、年齡層、性別和護理環境如何影響臨床選擇和資源分配

特定細分市場的動態揭示了治療方式、患者群體和照護端之間存在的微妙機會和摩擦點，直接影響臨床決策和商業策略。在治療類別中，抗生素仍然是急性護理的支柱，磷黴素、呋喃妥因和甲氧芐啶/磺胺甲噁唑等藥物根據療效特徵、給藥便利性、安全性考慮和管理重點，各自佔據著不同的臨床領域。同時，D-甘露糖、非那吡啶和益生菌等非抗生素療法正擴大被考慮用於緩解症狀、預防復發，或作為循證客製化護理計劃的輔助手段。

依年齡細分可揭示臨床病程和風險考慮的差異。對於成人患者，門診和遠端醫療模式通常有效，且往往提供簡單的管理途徑；而老年族群則需要關注合併症、多重用藥風險以及通常需要多學科協作的非典型病理。兒科護理強調基於體重的給藥、看護者教育和兒童友善處方，並受益於清晰的指導，以避免不必要的抗生素暴露。

性別差異會影響盛行率和治療方法。女性患者中併發症病例的比例較高，而男性患者較可能需要評估潛在的結構性和併發症因素。終端用戶細分凸顯了診所和醫院在診斷、升級和管理方面的互補作用，隨著醫療服務轉向門診管理和患者自我護理，居家照護環境的重要性日益凸顯。此類細分洞察有助於制定有針對性的臨床指南、處方決策和商業性推廣，從而根據特定人群和護理環境的需求客製化產品屬性。

針對亞太地區、歐洲、中東和非洲的區域策略考慮，以推動治療的採用、取得和供應鏈的彈性

臨床實務模式、法律規範和供應鏈整合的地區差異，導致各主要地區策略重點各異，進而影響尿道結石藥物的取得和採用。在美洲，公立和私立支付機構的混合、成熟的分銷網路以及較高的門診利用率，推動了對經濟高效、符合指南的治療方法和彈性物流的需求，以支持以地區為基礎的管理。該地區也正在快速普及遠端醫療和遠端監控，這正在影響治療方法的處方和實施方式。

在歐洲、中東和非洲地區，法規環境、報銷機制和基礎設施成熟度差異巨大，需要採取靈活的商業化方法。一些市場透過強力的抗生素管理計劃和集中採購來影響處方決策，而其他市場則專注於改善藥物的可及性和診斷能力。因此，製造商和服務供應商需要根據區域政策重點和醫療保健服務模式，調整其參與策略和供應方式。

亞太地區擁有充滿活力的製造地，以及快速發展的臨床市場。雖然該地區部分地區能夠實現大批量生產，支持全球供應，但由於監管途徑和處方習慣存在差異，需要調整打入市場策略。在每個地區，與當地經銷商夥伴關係、投資診斷能力以及遵循特定地區的臨床指南對於確保獲得適當的治療方法和持續的護理至關重要。

競爭格局分析確定了治療和服務導向相關人員之間的創新途徑、夥伴關係模式和商業化策略

專注於治療創新、診斷整合以及支持管理和以患者為中心的醫療服務交付模式的公司正在塑造尿道結石領域的競爭格局。大型製藥公司追求差異化的配方、給藥方案和安全性，以滿足臨床醫生和患者的偏好，而規模較小的專科公司則探索新型非抗生素輔助藥物和支持性護理藥物，以補充傳統療法。對於那些尋求精準治療決策並透過改善療效和減少不當抗生素使用來展現價值的公司來說，診斷與治療的交叉領域是一個不斷擴大的策略投資領域。

隨著各組織致力於加快產品上市速度、擴大通路並管理供應鏈風險，製造商、診斷供應商和分銷網路之間的夥伴關係與聯盟正變得越來越普遍。商業策略強調醫生教育、真實世界證據生成以及基於價值的合約模式，將獎勵與合理的使用和結果相結合。同時，對生產靈活性和品質保證的投資有助於應對政策變化和突發的供應中斷。

服務供應商和臨床機構也在不斷發展，出現了以門診病人管理、遠端醫療追蹤和病患教育為重點的整合照護模式。這些模式為能夠提供整合治療、診斷和數位化支援的捆綁式解決方案的公司創造了機會，能夠在依從性、復發預防和患者滿意度方面取得顯著改善。

為製造商、付款人和醫療保健提供者提供實用、高影響力的策略建議，以提高治療方法採用率、供應彈性和患者治療效果

產業領導者應優先考慮一系列策略行動，以提升臨床療效、供應韌性和商業性效益。首先，將產品開發和產品組合定位與管理原則和臨床醫生工作流程結合，將有助於推廣應用。這意味著要強調安全性、易用性以及與管理目標相輔相成的證據。其次，多樣化籌資策略並投資於供應鏈透明度，可以減少貿易政策中斷的風險，並確保診所、醫院和居家醫療機構的連續性。

第三，公司和醫療系統應擴大診斷整合力度，以實現更有針對性的治療選擇，並利用即時診斷工具和決策支持，最大限度地減少不必要的抗生素暴露。第四，根據細分市場的實際情況，制定個人化的參與方案，使治療特徵與成人、老年和小兒科的需求一致，並考慮性別特異性的臨床模式，這將改善處方調整和患者預後。第五，區域市場策略應在全球一致性與在地化適應性之間取得平衡，並考慮到美洲、歐洲、中東和非洲以及亞太地區不同的監管和報銷格局。

最後，製造商、付款人、供應商和經銷商之間的積極合作可以製定應對與資費相關的中斷的緊急時應對計畫，並建立基於價值的安排，以獎勵合理使用和可衡量的成果。這些措施合在一起，將增強韌性，提高醫療質量，並使相關人員能夠靈活應對臨床和政策變化。

透明的調查方法，詳細說明用於吸引相關人員、檢驗數據和產生可靠、可操作的見解的分析框架

本分析採用混合方法調查方法，結合一手資料和二手資料，旨在獲得可靠且可操作的見解。主要輸入包括與臨床醫生、藥劑師、供應鏈專家和商業領袖進行結構化訪談，以了解臨床實踐、採購限制和患者需求的真實觀點。此外，我們還對臨床指南、監管趨勢和技術應用趨勢進行了系統性回顧，以補充這些見解，從而為觀察到的行為和策略性反應提供背景資訊。

分析方法包括定性主題分析，透過相關人員訪談識別重複出現的模式，以及跨資料流的三角測量來檢驗結論。情境分析用於探索政策變化和供應鏈壓力源的潛在影響，並強調組織可以部署的營運槓桿。自始至終，我們強調假設的透明度和方法的可複製性，並與獨立的臨床和供應鏈專家進行反覆檢驗，以完善解釋並確保其實踐相關性。

在原始資料收集過程中，我們遵循了倫理考量和資料隱私通訊協定。本調查方法兼顧了深刻的見解和廣闊的視角，為決策者在尿道結石護理生態系統的策略發展和營運規劃中提供了堅實的基礎。

簡要概述關鍵發現和策略意義，為領導者應對不斷變化的尿道感染護理和交付環境提供指導

本文揭示了臨床實踐、患者期望、供應鏈動態和當地市場現實等相互關聯的力量，這些力量共同影響著尿道感染) 的治療。有效的尿道感染管理越來越依賴協調診斷準確性、治療選擇和管理原則，以維持治療效果並最佳化患者體驗。同時，供應鏈和政策制定需要積極主動的規劃，以維持持續的可近性，並在必要時支持實證替代治療。

決策者應將臨床介入和營運介入視為互補。在診斷、臨床醫生決策支援和患者教育方面的投資可以減少抗生素的不當使​​用並改善治療效果，而策略性採購和本地市場適應則可以確保藥物的可及性和商業性可行性。這種整合凸顯了臨床負責人、採購團隊和相關人員之間跨職能協作的必要性，以便將洞察轉化為醫療服務方面可衡量的改進。

隨著情況的不斷演變，那些整合了以管理為重點的產品策略、彈性供應方式和區域客製化商業化計劃的組織將最有能力提供高品質、以患者為中心的尿道結石治療，同時應對政策和市場的不確定性。持續監測診斷創新、臨床證據和貿易政策的趨勢，對於維持進展並長期調整策略至關重要。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 臨床環境中擴大採用快速診斷測試，提高了泌尿道感染管理的準確性和速度
  • 為了降低抗生素抗藥性，D-甘露糖和益生菌等非抗生素療法越來越受歡迎。
  • 開發針對泌尿道感染病原體的新型窄效抗生素以維持微生物群的完整性
  • 在基層醫療環境中擴大使用遠端醫療平台進行尿道感染的遠距離診斷和管理
  • 人工智慧演算法整合用於臨床決策支援系統中預測尿路感染復發風險分層
  • 擴大門診和社區診所的抗生素管理項目，以遏制不適當的泌尿道感染處方

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章尿道感染市場（按治療）

  • 抗生素
    • 磷黴素
    • 呋喃妥因
    • 甲氧芐啶/磺胺甲噁唑
  • 非抗生素療法
    • D-甘露糖
    • 非那吡啶
    • 益生菌

第9章尿道感染市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 10 章尿道感染市場：性別

  • 女士
  • 男性

第 11 章尿道感染市場（依最終用戶）

  • 診所
  • 居家照護環境
  • 醫院

第12章尿道感染市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章尿道感染市場：按組

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章尿道感染市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Johnson & Johnson
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Astellas Pharma Inc.
    • Bayer AG
Product Code: MRR-034B50030335

The Urinary Tract Infection Market is projected to grow by USD 21.66 billion at a CAGR of 7.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.47 billion
Estimated Year [2025] USD 13.34 billion
Forecast Year [2032] USD 21.66 billion
CAGR (%) 7.14%

A concise overview of evolving Urinary Tract Infection clinical dynamics, patient expectations, and stakeholder priorities reshaping diagnosis and treatment pathways

Urinary tract infections (UTIs) remain a pervasive clinical challenge that intersects primary care, ambulatory services, and acute care delivery. The clinical landscape is defined by evolving diagnostic approaches that prioritize rapid symptom triage and point-of-care testing, an expanding therapeutic toolkit that balances efficacy with antimicrobial stewardship, and heightened patient expectations for accessible, tolerable treatment options. These converging forces shape how clinicians, payers, and health systems set priorities when evaluating treatment pathways and service models.

Clinicians increasingly rely on integrated workflows that combine symptom assessment with targeted testing to distinguish uncomplicated presentations from cases requiring escalation. Simultaneously, pharmaceutical and non-pharmaceutical options are gaining attention not only for symptomatic relief but also for their roles in reducing recurrence and supporting antimicrobial stewardship. Patients and caregivers are seeking treatments that offer rapid symptom control, minimal adverse effects, and convenient delivery, and these preferences are influencing prescribing behavior as well as product development.

From an operational perspective, healthcare providers are adapting care pathways to accommodate telemedicine encounters, remote monitoring, and home-based management where appropriate, which underscores the need for robust clinical guidelines and patient education. Taken together, these dynamics set the stage for strategic decision-making across the value chain-from research and development to distribution and clinical implementation-requiring stakeholders to align clinical evidence, supply resilience, and patient-centered design.

Emerging clinical, technological, and behavioral shifts that are fundamentally transforming the Urinary Tract Infection care landscape and stakeholder decision-making

The UTI environment is undergoing transformative shifts driven by advances in diagnostics, renewed emphasis on antimicrobial stewardship, and patient behavior changes amplified by digital health adoption. Rapid molecular and point-of-care diagnostics are reducing diagnostic uncertainty, enabling clinicians to tailor therapy more precisely and avoid unnecessary broad-spectrum antibiotic use. This shift is reinforcing a clinical preference for targeted agents and supporting the integration of non-antibiotic adjuncts into care algorithms where appropriate.

Behavioral shifts are equally significant; patients now expect faster care access, greater transparency around risks and benefits, and options that align with lifestyle preferences. Telehealth has matured as a viable modality for initial assessment and follow-up, prompting care models that blend remote management with in-person escalation when indicated. Meanwhile, supply chain innovation, including closer alignment between manufacturers and distributors, is helping to mitigate episodic shortages and ensure treatment continuity across care settings.

Technological integration is beginning to reshape clinical workflows. Electronic health records and decision support systems are being updated to reflect stewardship principles and to prompt appropriate diagnostic testing. These tools facilitate better adherence monitoring and enable real-world evidence collection that informs iterative guideline updates. Collectively, these transformative forces are creating an ecosystem in which clinical effectiveness, patient experience, and operational resilience are increasingly interdependent.

Cumulative consequences of United States tariff measures in 2025 on pharmaceutical supply chains, procurement strategies, and clinical access across care environments

United States tariff actions in 2025 introduce a layer of complexity for supply chains, procurement strategies, and manufacturing footprint decisions that service the UTI treatment continuum. Tariff measures that affect raw materials, active pharmaceutical ingredients, or finished product imports can alter procurement economics, prompting manufacturers and distributors to reassess sourcing strategies and to evaluate the feasibility of shifting production or qualifying additional suppliers. In turn, health systems and payers may need to adjust contracting approaches to maintain access and to preserve therapeutic continuity across care settings.

Beyond procurement, tariffs can influence the cadence of inventory planning and the structure of commercial contracts. Organizations may increase safety stock levels or diversify supplier panels to reduce exposure to trade policy disruption, which has implications for working capital and logistics capacity. Manufacturers and service providers are likely to revisit nearshoring or regionalization strategies to reduce tariff risk, but such moves require lead time, capital investment, and regulatory coordination that can constrain immediate responsiveness.

Clinicians and formulary decision-makers should anticipate potential changes in product availability or substitutions that could require protocol adjustments and enhanced communication with patients. Payers and health systems may intensify collaboration with manufacturers to design contingency plans that preserve access to first-line therapies while aligning with stewardship goals. Ultimately, tariff-driven shifts reinforce the value of supply chain agility, diversified sourcing, and proactive stakeholder engagement to safeguard patient care during policy-induced market fluctuations.

Deep segmentation-driven insights demonstrating how treatment modalities, age cohorts, gender differentials, and care settings shape clinical choices and resource allocation

Segment-specific dynamics reveal nuanced opportunities and friction points across treatment modalities, patient populations, and points of care that directly impact clinical decision-making and commercial strategy. Within treatment categories, antibiotics remain central for acute management, with agents such as fosfomycin, nitrofurantoin, and trimethoprim/sulfamethoxazole each occupying distinct clinical niches based on efficacy profiles, dosing convenience, safety considerations, and stewardship priorities. Concurrently, non-antibiotic therapies such as D-mannose, phenazopyridine, and probiotic interventions are increasingly considered for symptom relief, recurrence prevention, or as adjuncts in tailored care plans where evidence supports their use.

Age-based segmentation highlights differential clinical pathways and risk considerations. Adults tend to present with straightforward management pathways where outpatient and telehealth models are commonly effective, while geriatric populations require heightened attention to comorbidities, polypharmacy risks, and atypical presentations that often necessitate multi-disciplinary coordination. Pediatric care emphasizes weight-based dosing, caregiver education, and child-friendly formulations, and it benefits from clear guidance to avoid unnecessary antibiotic exposure.

Gender-based differences influence both incidence and management approaches, with female patients representing a larger proportion of uncomplicated presentations and male patients more likely to prompt evaluation for underlying structural or complicating factors. End-user segmentation clarifies where value is realized: clinics and hospitals each play complementary roles in diagnosis, escalation, and stewardship, and home care settings are increasingly important as care delivery shifts toward ambulatory management and patient self-care initiatives. These segmentation insights inform targeted clinical guidelines, formulary decisions, and commercial outreach that align product attributes to the needs of specific populations and care settings.

Regional strategic considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific that drive treatment adoption, access, and supply chain resilience

Regional variation in clinical practice patterns, regulatory frameworks, and supply chain integration creates distinct strategic priorities across major geographies that affect access to and adoption of UTI therapies. In the Americas, a mix of public and private payers, established distribution networks, and a high degree of outpatient care utilization emphasize the need for cost-effective, guideline-aligned therapies and resilient logistics to support community-based management. This region also shows rapid uptake of telemedicine and remote monitoring, which influences how treatments are prescribed and delivered.

Within Europe, the Middle East & Africa, heterogeneity is pronounced: regulatory environments, reimbursement mechanisms, and infrastructure maturity differ widely, necessitating flexible commercialization approaches. Some markets have strong antimicrobial stewardship programs and centralized procurement that shape formulary decisions, while others are focused on improving access and diagnostic capacity. Manufacturers and service providers must therefore tailor engagement strategies and supply approaches to account for local policy priorities and healthcare delivery models.

The Asia-Pacific region features dynamic manufacturing hubs alongside markets with rapidly evolving clinical practices. High-volume production capacity in parts of this region supports global supply, but divergent regulatory pathways and localized prescribing habits require adaptive market access strategies. Across all regions, partnerships with local distributors, investments in diagnostic capacity, and responsiveness to region-specific clinical guidelines remain critical to ensuring appropriate therapy utilization and continuity of care.

Competitive landscape analysis revealing innovation pathways, partnership models, and commercialization strategies among therapeutic and service-oriented stakeholders

Competitive dynamics in the UTI space are shaped by companies that focus on therapeutic innovation, diagnostic integration, and service delivery models that support stewardship and patient-centric care. Leading pharmaceutical players pursue differentiated formulations, dosing regimens, and safety profiles to address clinician and patient preferences, while smaller specialty companies explore novel non-antibiotic adjuncts and symptomatic agents that can complement traditional therapy. The intersection of diagnostics and therapeutics is a growing area of strategic investment as companies seek to enable targeted treatment decisions and to demonstrate value through improved outcomes and reduced inappropriate antibiotic use.

Partnerships and alliances between manufacturers, diagnostic providers, and distribution networks are increasingly common as organizations aim to accelerate time-to-market, expand access, and manage supply chain risk. Commercial strategies emphasize physician education, real-world evidence generation, and value-based contracting approaches that align incentives around appropriate use and outcomes. At the same time, investment in manufacturing flexibility and quality assurance helps companies respond to policy shifts and episodic supply disruptions.

Service providers and clinical organizations are also evolving, with integrated care models that prioritize outpatient management, telehealth-enabled follow-up, and patient education. These models create opportunities for companies that can offer bundled solutions-combining therapeutics, diagnostics, and digital support-to demonstrate measurable improvements in adherence, recurrence reduction, and patient satisfaction.

Practical, high-impact strategic recommendations for manufacturers, payers, and providers to enhance therapy adoption, supply resilience, and patient outcomes

Industry leaders should prioritize a set of strategic actions to strengthen clinical outcomes, supply resilience, and commercial effectiveness. First, aligning product development and portfolio positioning with stewardship principles and clinician workflow will support adoption; this means emphasizing safety profiles, dosing simplicity, and evidence that complements stewardship goals. Second, diversifying sourcing strategies and investing in supply chain transparency can reduce exposure to trade policy disruptions and ensure continuity across clinics, hospitals, and home care settings.

Third, companies and health systems should expand diagnostic integration efforts to enable more targeted therapy selection, leveraging point-of-care tools and decision support to minimize unnecessary antibiotic exposure. Fourth, tailored engagement that reflects segmentation realities-matching therapeutic attributes to the needs of adults, geriatrics, and pediatrics, and considering gender-specific clinical patterns-will improve prescribing alignment and patient outcomes. Fifth, regional market strategies should balance global consistency with local adaptation, recognizing the distinct regulatory and reimbursement landscapes across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Finally, proactive collaboration among manufacturers, payers, providers, and distributors can create contingency plans for tariff-related disruptions and establish value-based arrangements that reward appropriate use and measurable outcomes. Executed in concert, these steps enhance resilience, elevate care quality, and position stakeholders to respond nimbly to clinical and policy shifts.

Transparent research methodology detailing stakeholder engagement, data validation, and analytical frameworks used to generate robust and actionable insights

This analysis draws on a mixed-methods research approach combining primary stakeholder engagement, secondary literature synthesis, and cross-functional validation to ensure robust and actionable findings. Primary inputs included structured interviews with clinicians, pharmacists, supply chain professionals, and commercial leaders to capture real-world perspectives on clinical practice, procurement constraints, and patient needs. These insights were complemented by a systematic review of clinical guidelines, regulatory developments, and technology adoption trends to contextualize observed behaviors and strategic responses.

Analytical techniques included qualitative thematic analysis to identify recurring patterns across stakeholder interviews, and triangulation across data streams to validate conclusions. Scenario analysis was used to explore plausible impacts of policy shifts and supply chain stressors, focusing on operational levers that organizations can deploy. Throughout, emphasis was placed on transparency in assumptions and reproducibility of methods, with iterative validation sessions conducted with independent clinical and supply chain experts to refine interpretations and ensure practical relevance.

Ethical considerations and data privacy protocols were observed during primary data collection. The methodology balances depth of insight with breadth of perspective, providing decision-makers with a defensible foundation for strategy development and operational planning within the UTI care ecosystem.

Concise synthesis of critical findings and strategic implications for leaders navigating the evolving Urinary Tract Infection care and supply environment

This synthesis highlights the interconnected nature of clinical practice, patient expectations, supply chain dynamics, and regional market realities that collectively shape UTI care. Effective management of urinary tract infections increasingly depends on aligning diagnostic precision, therapeutic choice, and stewardship principles to preserve treatment efficacy and optimize patient experience. In parallel, supply chain and policy developments require proactive planning to maintain uninterrupted access and to support evidence-based substitution where necessary.

Decision-makers should view clinical and operational interventions as complementary: investments in diagnostics, clinician decision support, and patient education reduce inappropriate antibiotic use and improve outcomes, while strategic sourcing and regional market adaptation preserve access and commercial viability. The convergence of these elements underscores the need for cross-functional collaboration among clinical leaders, procurement teams, and commercial stakeholders to translate insights into measurable improvements in care delivery.

As the landscape continues to evolve, organizations that integrate stewardship-minded product strategies, resilient supply approaches, and regionally attuned commercialization plans will be best positioned to deliver high-quality, patient-centered UTI care while navigating policy and market uncertainties. Continued monitoring of diagnostic innovations, clinical evidence, and trade policy developments will be essential to sustain progress and adapt strategies over time.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of point-of-care rapid diagnostic tests enhancing UTI management accuracy and speed
  • 5.2. Growing preference for non-antibiotic therapies such as D-mannose and probiotics to reduce antibiotic resistance
  • 5.3. Development of novel narrow-spectrum antibiotics targeting UTI pathogens to preserve microbiome integrity
  • 5.4. Increasing utilization of telehealth platforms for remote diagnosis and management of urinary tract infections in primary care settings
  • 5.5. Integration of artificial intelligence algorithms for predictive UTI recurrence risk stratification in clinical decision support systems
  • 5.6. Expansion of antimicrobial stewardship programs within outpatient and community clinics to curb inappropriate UTI prescriptions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urinary Tract Infection Market, by Treatment

  • 8.1. Antibiotics
    • 8.1.1. Fosfomycin
    • 8.1.2. Nitrofurantoin
    • 8.1.3. Trimethoprim/Sulfamethoxazole
  • 8.2. Non Antibiotic Therapies
    • 8.2.1. D Mannose
    • 8.2.2. Phenazopyridine
    • 8.2.3. Probiotics

9. Urinary Tract Infection Market, by Age Group

  • 9.1. Adults
  • 9.2. Geriatrics
  • 9.3. Pediatrics

10. Urinary Tract Infection Market, by Gender

  • 10.1. Female
  • 10.2. Male

11. Urinary Tract Infection Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Urinary Tract Infection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Urinary Tract Infection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Urinary Tract Infection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. F. Hoffmann-La Roche Ltd
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Merck & Co., Inc.
    • 15.3.5. GlaxoSmithKline plc
    • 15.3.6. Abbott Laboratories
    • 15.3.7. Thermo Fisher Scientific Inc.
    • 15.3.8. Danaher Corporation
    • 15.3.9. Astellas Pharma Inc.
    • 15.3.10. Bayer AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FOSFOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NITROFURANTOIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TRIMETHOPRIM/SULFAMETHOXAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY D MANNOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PHENAZOPYRIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. GCC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GCC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GCC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 246. GCC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 247. GCC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 248. GCC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 249. GCC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. GCC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. GCC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GCC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GCC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 254. GCC URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 255. GCC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. GCC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. G7 URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. G7 URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. G7 URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 288. G7 URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 289. G7 URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 290. G7 URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 291. G7 URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 292. G7 URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 293. G7 URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. G7 URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. G7 URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 296. G7 URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 297. G7 URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. G7 URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NATO URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. NATO URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. NATO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 302. NATO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 303. NATO URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 304. NATO URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 305. NATO URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 306. NATO URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 307. NATO URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. NATO URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. NATO URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 310. NATO URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 311. NATO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. NATO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA URINARY TRACT INFECT